Lineage Cell (LCTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +100.00%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.02 per share when it actually produced a loss of $0.13, delivering a surprise of -550%.Over the last four quarters, the company ...

分组1 - Ocugen reported a quarterly loss of $0.06 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.05 per share a year ago [1] - The company posted revenues of -$0.19 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 112.87%, and down from $0.76 million year-over-year [2] - Over the last four quarters, Ocugen has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] 分组2 - Ocugen shares have increased by approximately 37.8% since the beginning of the year, while the S&P 500 has declined by 0.4% [3] - The company's earnings outlook, including current consensus earnings expectations, will be crucial for future stock performance [4] - The current consensus EPS estimate for the coming quarter is -$0.07 on $1 million in revenues, and -$0.26 on $5.7 million in revenues for the current fiscal year [7] 分组3 - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 44% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ocugen's stock performance [5][6]

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +34.31%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.28, delivering a surprise of +20%.Over the last four quarters, the company ha ...

Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1,053.85%. A quarter ago, it was expected that this drug developer would post a loss of $0.09 per share when it actually produced a loss of $0.07, delivering a surprise of +22.22%.Over the last four quarters, the company ha ...

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.6 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.3, delivering a surprise of +14.29%.Over the last four quarters, the company ...

分组1 - PTC Therapeutics reported a quarterly loss of $1.67 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.21, representing an earnings surprise of -700.58% [1] - The company posted revenues of $164.68 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 45.96%, compared to year-ago revenues of $213.17 million [2] - PTC Therapeutics shares have underperformed the market, losing about 9.3% since the beginning of the year, while the S&P 500 gained 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$0.58 on revenues of $206 million, and for the current fiscal year, it is -$1.60 on revenues of $959.42 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Ovid Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.10 per share, with revenues projected to be $0.24 million, reflecting a year-over-year increase of 203.8% [9]

分组1 - Halozyme Therapeutics reported a quarterly loss of $0.24 per share, significantly below the Zacks Consensus Estimate of $2.15, marking an earnings surprise of -111.16% compared to earnings of $1.26 per share a year ago [1] - The company posted revenues of $451.77 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 0.70% and showing a year-over-year increase from $298.01 million [2] - Halozyme Therapeutics has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has increased approximately 18% since the beginning of the year, while the S&P 500 has declined by 0.1% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for future stock performance [4] - The current consensus EPS estimate for the next quarter is $1.66 on revenues of $366.53 million, and for the current fiscal year, it is $8.10 on revenues of $1.74 billion [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Halozyme belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5] - The estimate revisions trend for Halozyme was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Core Viewpoint - Apellis Pharmaceuticals, Inc. (APLS) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ending December 2025, with a consensus outlook indicating a potential impact on its near-term stock price [1]. Financial Performance Expectations - The upcoming earnings report is expected to be released on February 24, and if the results exceed expectations, the stock may rise; conversely, missing estimates could lead to a decline [2]. - The consensus estimate predicts a quarterly loss of $0.39 per share, reflecting a year-over-year change of -34.5%, with revenues projected at $194.37 million, down 8.5% from the previous year [3]. Estimate Revisions Trend - Over the last 30 days, the consensus EPS estimate has been revised 0.84% higher, indicating a reassessment by covering analysts [4]. - The Most Accurate Estimate for Apellis is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -3.07%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, with a positive ESP being a strong predictor of an earnings beat [9][10]. - Apellis currently holds a Zacks Rank of 3, which complicates the prediction of an earnings beat given the negative Earnings ESP [12]. Historical Performance - In the last reported quarter, Apellis was expected to post earnings of $1.03 per share but delivered $1.67, resulting in a surprise of +62.14% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Industry Comparison - In contrast, Axsome Therapeutics (AXSM), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post a loss of $0.7 per share for the same quarter, with revenues projected to be $193.01 million, up 62.5% year-over-year [18]. - Axsome's consensus EPS estimate has been revised 9.2% higher in the last 30 days, resulting in a positive Earnings ESP of +43.57%, suggesting a likely earnings beat [19][20].

分组1 - NeoGenomics reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, and showing an increase from $0.04 per share a year ago, resulting in an earnings surprise of +57.90% [1] - The company achieved revenues of $190.17 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.90%, and up from $172 million in the same quarter last year [2] - Over the last four quarters, NeoGenomics has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] 分组2 - The stock has underperformed the market with a decline of about 3.2% since the beginning of the year, compared to the S&P 500's decline of 0.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.02 on revenues of $188.18 million, and for the current fiscal year, it is $0.18 on revenues of $795 million [7] - The Medical - Biomedical and Genetics industry, to which NeoGenomics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

分组1 - Moderna reported a quarterly loss of $2.11 per share, better than the Zacks Consensus Estimate of a loss of $2.6, and an improvement from a loss of $2.5 per share a year ago, resulting in an earnings surprise of +18.75% [1] - The company achieved revenues of $678 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.81%, although this represents a decline from year-ago revenues of $966 million [2] - Moderna has outperformed the S&P 500, with shares increasing by about 36% since the beginning of the year, while the S&P 500 has declined by 0.2% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$2.14 on revenues of $254.87 million, and for the current fiscal year, it is -$6.70 on revenues of $2.09 billion [7] - The Medical - Biomedical and Genetics industry, to which Moderna belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]